Skip to content
    Clinical Trials

    FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

    FDAFDA What's New: Drugs

    FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
    The U.S. Food and Drug Administration (FDA) has approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor targeting the RAS GTPase family. This approval is indicated for adult patients with metastatic pancreatic adenocarcinoma who have progressed on or after at least one prior systemic therapy, or who are not suitable candidates for multiagent systemic therapy.

    Key Takeaways

    • The FDA has approved daraxonrasib (RASONQUE), a RAS GTPase family inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are ineligible for multiagent systemic therapy.
    Read the original sourceFDA What's New: Drugs